Dimension Therapeutics | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (25)

View All

Latest Posts

About This Stock More About This Stock
The 3 Best Developmental Stage Biotech Stocks Surging Now
Article By: Zacks Investment Research
Wednesday, May 25, 2016 10:54 PM EDT
Every week, there are small, under-the-radar companies that see their share prices surge immensely. Not all of these companies are worth being bullish on, but the Zacks Rank helps to find companies that might be worth taking a chance on.
In this article: GLYC, VTAE, DMTX
Read
Dimension Therapeutics Downgraded To Neutral From Buy At Goldman
Article By: The Fly
Wednesday, March 30, 2016 7:57 AM EDT
The analyst views Dimension as well-positioned in the gene therapy space, however. He lowered his price target for the shares to $10 from $12.
In this article: DMTX Also: ACOR, SAGE
Read
Early Stage Status For Dimension Therapeutics Keeps Us Cautious On This IPO
Article By: Don Dion
Friday, October 23, 2015 11:59 AM EDT
Dimension Therapeutics expects to raise $82.5 million in its upcoming IPO. Based in Cambridge, Massachusetts, it is a biotechnology company with a gene therapy platform for developing treatments for rare diseases associated with the liver.
In this article: NVO, PFE, QURE, ONCE, BXLT, DMTX
Read
All Posts

Latest Tweets for $DMTX

No tweets yet!

PARTNER HEADLINES